Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | E180R |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 E180R lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). E180R demonstrates reduced DNA-binding cooperativity, and results in decreased DNA binding affinity, leading to reduced expression of BAX and PUMA, and reduced repression of target genes in cell culture (PMID: 23966881, PMID: 16035029). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon5 TP53 E180R TP53 mutant TP53 inact mut TP53 E180R |
Transcript | NM_000546.6 |
gDNA | chr17:g.7675073_7675074delGAinsAG |
cDNA | c.538_539delGAinsAG |
Protein | p.E180R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126112.3 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276697 | chr17:g.7670693_7670694delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276697.1 | chr17:g.7670693_7670694delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276697.3 | chr17:g.7670693_7670694delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7675073_7675074delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276698.3 | chr17:g.7673317_7673318delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276698.1 | chr17:g.7673317_7673318delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7675073_7675074delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7675073_7675074delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7675073_7675074delGAinsAG | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7675073_7675074delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
NM_001276698 | chr17:g.7673317_7673318delTCinsCT | c.538_539delGAinsAG | p.E180R | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 E180R | acute myeloid leukemia | sensitive | Cytarabine + Doxorubicin | Preclinical | Actionable | In a preclinical study, the combination of Cytosar-U (cytarabine) and Adriamycin (doxorubicin) inhibited tumor growth and increased survival (p<0.0001) compared to control treatment in a mouse model of acute myeloid leukemia harboring TP53 E177R (corresponding to E180R in human) (PMID: 34907344). | 34907344 |